Leah Monteiro

Investor Relations Contact at SOLID BIOSCIENCES INC.

Health Technology

Profile

Leah Monteiro is currently the Vice President of Investor Relations & Communications at Solid Biosciences, Inc. Prior to her current position, she worked as the Senior Director of Communications & IR at KalVista Pharmaceuticals, Inc. from 2016 to 2021.
She also served as the Vice President of Investor Relations at DURECT Corp.
and as the Senior Manager of Investor Relations at Genzyme Corp.
Additionally, she worked as the Manager of Corporate Communications at Sesen Bio, Inc.

Leah Monteiro active positions

Companies	Position	Start
SOLID BIOSCIENCES INC.	Investor Relations Contact	-

All active positions of Leah Monteiro

Former positions of Leah Monteiro

Companies	Position	End
KALVISTA PHARMACEUTICALS, INC.	Investor Relations Contact	2021-11-30
CARISMA THERAPEUTICS, INC.	Investor Relations Contact	2016-06-30
DURECT CORPORATION	Investor Relations Contact	-
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Investor Relations Contact	-

See the detail of Leah Monteiro's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Leah Monteiro's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
KALVISTA PHARMACEUTICALS, INC.	Health Technology
DURECT CORPORATION	Health Technology
SOLID BIOSCIENCES INC.	Health Technology

Private companies	2
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Health Technology
Sesen Bio, Inc. Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.	Health Technology